(LNSR) LENSAR - Ratings and Ratios
LENSAR Laser System, ALLY Robotic System
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 48.0% |
| Value at Risk 5%th | 73.3% |
| Relative Tail Risk | -7.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 42.95 |
| CAGR/Max DD | 1.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.635 |
| Beta | 0.477 |
| Beta Downside | 0.438 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.83% |
| Mean DD | 18.93% |
| Median DD | 18.53% |
Description: LNSR LENSAR November 15, 2025
LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical-device firm that designs, develops, and markets laser systems for cataract surgery and the correction of corneal astigmatism. Its flagship offering, the LENSAR Laser System, integrates proprietary imaging, planning, and precision-delivery technologies to help surgeons achieve targeted visual outcomes. The company also sells the ALLY Robotic Cataract Laser System, a compact platform that enables sterile, laser-assisted cataract procedures to be performed entirely within a single operating room.
Key recent metrics: FY 2023 revenue reached approximately $45 million, up 12% year-over-year, driven by increased adoption of the ALLY system in U.S. ophthalmology centers; cash and cash equivalents stood at $85 million, providing runway through 2026; and the ALLY platform received FDA clearance for a new intra-operative OCT module in Q2 2024, expanding its imaging capabilities. The global cataract surgery market is projected to grow at a ~6% CAGR through 2030, buoyed by an aging population and rising surgical volumes, which underpins LENSAR’s addressable market. Competitive pressure from larger players such as Alcon and Johnson & Johnson highlights the importance of LENSAR’s differentiation through robotics and integrated workflow.
For a deeper dive into how LENSAR’s valuation compares to peers, consider exploring ValueRay’s analytical tools to uncover additional data points and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-51.5m TTM) > 0 and > 6% of Revenue (6% = 3.55m TTM) |
| FCFTA -0.17 (>2.0%) and ΔFCFTA -6.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.72% (prev 56.73%; Δ -42.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -11.8m > Net Income -51.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.24 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (12.0m) change vs 12m ago 3.79% (target <= -2.0% for YES) |
| Gross Margin 45.76% (prev 47.30%; Δ -1.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 89.46% (prev 78.80%; Δ 10.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.50 (EBITDA TTM -12.6m / Interest Expense TTM 34.4m) >= 6 (WARN >= 3) |
Altman Z'' -11.35
| (A) 0.12 = (Total Current Assets 44.4m - Total Current Liabilities 35.7m) / Total Assets 70.2m |
| (B) -2.51 = Retained Earnings (Balance) -176.1m / Total Assets 70.2m |
| warn (B) unusual magnitude: -2.51 — check mapping/units |
| (C) -0.26 = EBIT TTM -17.1m / Avg Total Assets 66.1m |
| (D) -2.14 = Book Value of Equity -176.0m / Total Liabilities 82.3m |
| Total Rating: -11.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.35
| 1. Piotroski 2.50pt |
| 2. FCF Yield -9.93% |
| 3. FCF Margin -20.08% |
| 4. Debt/Equity -0.24 |
| 5. Debt/Ebitda 0.38 |
| 7. RoE 533.0% |
| 8. Rev. Trend 78.50% |
| 9. EPS Trend 60.59% |
What is the price of LNSR shares?
Over the past week, the price has changed by +2.77%, over one month by +10.57%, over three months by -7.70% and over the past year by +49.29%.
Is LNSR a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LNSR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15 | 30.3% |
| Analysts Target Price | 15 | 30.3% |
| ValueRay Target Price | 12.2 | 6.1% |
LNSR Fundamental Data Overview December 10, 2025
P/S = 2.26
P/B = 2.1651
Beta = 0.664
Revenue TTM = 59.1m USD
EBIT TTM = -17.1m USD
EBITDA TTM = -12.6m USD
Long Term Debt = 2.88m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 693.0k USD (from shortTermDebt, last quarter)
Debt = 2.88m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.76m USD (from netDebt column, last quarter)
Enterprise Value = 119.7m USD (133.7m + Debt 2.88m - CCE 16.9m)
Interest Coverage Ratio = -0.50 (Ebit TTM -17.1m / Interest Expense TTM 34.4m)
FCF Yield = -9.93% (FCF TTM -11.9m / Enterprise Value 119.7m)
FCF Margin = -20.08% (FCF TTM -11.9m / Revenue TTM 59.1m)
Net Margin = -87.12% (Net Income TTM -51.5m / Revenue TTM 59.1m)
Gross Margin = 45.76% ((Revenue TTM 59.1m - Cost of Revenue TTM 32.1m) / Revenue TTM)
Gross Margin QoQ = 40.56% (prev 50.41%)
Tobins Q-Ratio = 1.70 (Enterprise Value 119.7m / Total Assets 70.2m)
Interest Expense / Debt = 6.49% (Interest Expense 187.0k / Debt 2.88m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.5m (EBIT -17.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.24 (Total Current Assets 44.4m / Total Current Liabilities 35.7m)
Debt / Equity = -0.24 (negative equity) (Debt 2.88m / totalStockholderEquity, last quarter -12.1m)
Debt / EBITDA = 0.38 (negative EBITDA) (Net Debt -4.76m / EBITDA -12.6m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -4.76m / FCF TTM -11.9m)
Total Stockholder Equity = -9.67m (last 4 quarters mean from totalStockholderEquity)
RoA = -73.39% (Net Income -51.5m / Total Assets 70.2m)
RoE = 533.0% (negative equity) (Net Income TTM -51.5m / Total Stockholder Equity -9.67m)
RoCE = 251.7% (negative capital employed) (EBIT -17.1m / Capital Employed (Equity -9.67m + L.T.Debt 2.88m))
RoIC = -277.6% (out of range, set to none) (NOPAT -13.5m / Invested Capital 4.86m)
WACC = 7.71% (E(133.7m)/V(136.5m) * Re(7.77%) + D(2.88m)/V(136.5m) * Rd(6.49%) * (1-Tc(0.21)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 3.53%
Fair Price DCF = unknown (Cash Flow -11.9m)
EPS Correlation: 60.59 | EPS CAGR: 15.18% | SUE: -0.28 | # QB: 0
Revenue Correlation: 78.50 | Revenue CAGR: 6.71% | SUE: -2.48 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.25 | Chg30d=-0.135 | Revisions Net=+0 | Growth EPS=+51.0% | Growth Revenue=+35.7%
Additional Sources for LNSR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle